Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the virtual presentation of preclinical findings on BT7480, an innovative Nectin-4/CD137 tumor-targeted immune cell agonist (TICATM), at the AACR Annual Meeting on April 10-15, 2021. The company will also showcase additional data on TICAs and Bicycle Toxin Conjugates (BTCs) through various sessions and e-posters. BT7480 is expected to enter clinical trials in H2 2021, highlighting Bicycle's commitment to advancing its immuno-oncology pipeline.
Bicycle Therapeutics (NASDAQ: BCYC) has announced progress updates on its bicyclic peptide technology and partnered programs beyond oncology. The company has achieved its first milestone in collaboration with the Dementia Discovery Fund, focusing on TREM2 and transferrin receptor 1 targets. Additionally, it received funding to develop antimicrobial agents and COVID-19 solutions. Collaborations with AstraZeneca and Bioverativ continue, with assets being advanced for respiratory diseases and rare hematological conditions. Four Bicycle molecules are now in clinical trials, indicating potential for new treatments.
Bicycle Therapeutics (NASDAQ: BCYC) announces the appointment of Dr. Jose-Carlos Gutierrez-Ramos to its Board of Directors. With extensive experience in biopharmaceuticals, Dr. Gutierrez-Ramos aims to leverage his background in drug development to enhance Bicycle’s clinical oncology pipeline. CEO Kevin Lee highlights his invaluable contributions to the company’s ongoing success. Bicycle, known for its innovative Bicycle® technology, is advancing multiple clinical trials, including BT1718 and BT5528, targeting significant unmet medical needs.
Bicycle Therapeutics, a biotechnology company specializing in innovative therapeutics, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 8:40 a.m. ET. The event will be conducted virtually and will be accessible via a live webcast on Bicycle's website. Additionally, an archived replay will be available for 90 days post-event. Bicycle is known for its proprietary Bicycles technology, with ongoing clinical trials for its lead product candidate, BT1718, and additional candidates BT5528 and BT8009.
Bicycle Therapeutics (NASDAQ: BCYC) reported its fourth-quarter and full-year 2020 financial results, highlighting significant advancements despite COVID-19 challenges. The company has progressed multiple Bicycle Toxin Conjugates (BTCs) and is preparing for the clinical start of its first tumor-targeted immune cell agonist (TICA). Financially, Bicycle ended 2020 with $136 million in cash, up from $92 million in 2019, driven by successful fundraising efforts. However, the company reported a net loss of $51 million for 2020, with increased expenses in research and development and general administration.
Bicycle Therapeutics (NASDAQ:BCYC) announced the publication of preclinical studies on its innovative synthetic tumor-targeted immune cell agonists (TICAs) in the Journal for ImmunoTherapy of Cancer. The research highlights the potential of TICAs to enhance anticancer immunity through the modulation of CD137. Findings demonstrated that TICAs could efficiently co-stimulate human immune cells and eliminate tumors in preclinical models. The company plans to initiate a clinical trial for its lead TICA, BT7480, within the year, showcasing its commitment to advancing cancer immunotherapy.
Bicycle Therapeutics plc (NASDAQ: BCYC) reported notable advancements in its oncology pipeline, emphasizing its next-generation Bicycle Toxin Conjugates (BTCs) and tumor-targeted immune cell agonists (TICAs). Key programs include BT1718, which is in Phase IIa trials showing signs of anti-tumor activity, and BT5528, which has demonstrated preliminary efficacy in the ongoing Phase I trial. The company is also on track to expand its clinical trials for BT8009 and BT7480, with expectations for multiple clinical updates in 2021. Overall, Bicycle is positioning itself for significant milestones ahead.
Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in the virtual 2020 Piper Sandler Healthcare Conference from December 1-3, 2020. The management will engage in a fireside chat on December 1 at 9:00 a.m. ET. Interested parties can access a recording in the Investors & Media section of Bicycle's website, which will be available for 90 days post-event. Bicycle Therapeutics is developing innovative therapeutics known as Bicycles, with ongoing clinical trials for its lead product candidate, BT1718, and others targeting various tumor antigens.
Bicycle Therapeutics (NASDAQ: BCYC) has entered into a settlement and license agreement with Pepscan Systems B.V. regarding the use of CLIPS peptide technology. The settlement resolves all intellectual property disputes and allows Bicycle to utilize this technology for product candidates BT1718 and THR-149. Bicycle will pay €3 million upfront, with an additional €1 million due on the first anniversary, plus potential milestone payments. This agreement is aimed at advancing Bicycle's clinical development efforts in the biopharmaceutical sector.
Bicycle Therapeutics plc (NASDAQ: BCYC) will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 1:10 p.m. ET. The chat will be available via a live webcast on Bicycle's website, with an archived replay accessible for 90 days post-event. Bicycle Therapeutics is advancing a new class of therapeutics called Bicycles that target underserved diseases. Their lead candidate, BT1718, is undergoing trials focusing on cancer treatment.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
